


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. - 111. (cancelled)

112. (new) A pharmaceutical or cosmetic composition comprising at least one of a pharmaceutically or cosmetically acceptable carrier and a pharmaceutically or cosmetically acceptable adjuvant and at least one active ingredient selected from compounds of formula (I), including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, tautomers and stereoisomers thereof:




wherein

- X and Z each represent CH, CR₃ or N and at least one of X and Z is N;
- partial rings may be substituted or unsubstituted, condensed or noncondensed and may contain zero to three double bonds and zero to four heteroatoms and heteroatom-containing groups, the heteroatoms being selected from N, O and S;
- R₃ is selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁ to C₁₂ alkyl, C₂ to C₁₂ alkenyl and C₂ to C₁₂ alkynyl, hydroxy, thiol, C₁ to C₁₂ alkoxy, C₁ to C₁₂


alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;

- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula (I) via a C atom or a heteroatom; and
- ring systems of the compounds of formula (I) may contain zero to three double bonds.

113. (new) The composition of claim 112, wherein the composition comprises an active ingredient of formula



114. (new) The composition of claim 112, wherein the composition comprises an active ingredient of formula



P29678.A06

115. (new) The composition of claim 112, wherein the composition is a pharmaceutical composition which is suitable for use in a method of inhibiting an activity of at least one enzyme selected from dipeptidyl peptidase IV and analogous enzymes in a subject in need thereof.

116. (new) The composition of claim 113, wherein the composition is a pharmaceutical composition which is suitable for use in a method of inhibiting an activity of at least one enzyme selected from dipeptidyl peptidase IV and analogous enzymes in a subject in need thereof.

117. (new) The composition of claim 114, wherein the composition is a pharmaceutical composition which is suitable for use in a method of inhibiting an activity of at least one enzyme selected from dipeptidyl peptidase IV and analogous enzymes in a subject in need thereof.

118. (new) The composition of claim 112, wherein the composition is comprised in a coating of a stent.

119. (new) The composition of claim 112, wherein the composition is suitable for topical administration.

120. (new) The composition of claim 112, wherein the composition is suitable for at least one of oral, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular and intrathecal administration.

P29678.A06

121. (new) The composition of claim 112, wherein the composition is present as cream, an ointment, a paste, and a gel.

122. (new) The composition of claim 112, wherein the composition is present in combination with at least one of a depot matrix, a hydrocolloid dressing, a plaster, a micro-sponge and a prepolymer.

123. (new) The composition of claim 112, wherein the composition is suitable for use as a cosmetic composition.

124. (new) A method of inhibiting an activity of at least one enzyme selected from dipeptidyl peptidase IV and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject the composition of claim 112, alone or in combination with one or more inhibitors of alanyl aminopeptidase or analogous enzymes.

125. (new) A method of topically influencing an activity of at least one enzyme selected from dipeptidyl peptidase IV and analogous enzymes in a subject in need thereof, wherein the method comprises topically administering to the subject the composition of claim 112, alone or in combination with one or more inhibitors of alanyl aminopeptidase or analogous enzymes.

126. (new) A method of preventing or treating at least one condition selected from multiple sclerosis, Morbus Crohn, Colitis ulcerosa and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale and other allergic diseases; rejection of transplanted tissues and cells; skin and mucosa diseases such as psoriasis and acne; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts, preferably of benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states; acute neuronal diseases, in particular ischemia-caused cerebral damage after an ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease, Progressive Supranuclear Palsy, corticobasal degeneration, frontotemporal dementia, Morbus Parkinson, in particular Morbus Parkinson coupled to chromosome 17, Morbus Huntington, prion-caused diseases and amyotrophic lateral sclerosis; chronic obstructive pulmonal disease (COPD); prostata carcinoma and other tumors as well as metastases; Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-like conditions; in a subject in need thereof, wherein the method comprises administering to the subject the composition of claim 112 in an amount which is sufficient for preventing or treating the at least one condition.

127. (new) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, vasculitides, reperfusion syndrome and stent restenosis, for example after a percutaneous transluminal angioplasty, in a subject in need thereof, wherein the

P29678.A06

method comprises administering to the subject the composition of claim 112 in an amount which is sufficient for preventing or treating the at least one condition.

128. (new) The method of claim 127, wherein the method comprises administering the composition by using a stent which is coated with the composition.

129. (new) A method of preventing or treating an inflammation reaction at, or caused by, a medical device implanted into an organism, wherein the method comprises administering to the organism the composition of claim 112 in an amount which is sufficient for preventing or treating the inflammation reaction.

130. (new) The method of claim 129, wherein the method comprises administering the composition at least one of as a coating or layer on the medical device and incorporated in the medical device.

131. (new) The method of claim 129, wherein the method comprises administering the composition by at least one of a local and a systemic administration successively or concurrently.